| Coronary effects of exogenous and endogenous bradykinin in conscious dogs. | |
| | |
MedLine Citation:
|
PMID: 9263762 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The effects of intravenous (iv) bolus administrations of bradykinin (0.1-1 microgram.kg-1) on large and small coronary arteries were investigated in seven chronically instrumented conscious dogs. Bradykinin dose-dependently increased heart rate, left ventricular dP/dt max, coronary blood flow and coronary artery diameter and decreased aortic pressure. Subchronic inhibition of the nitric oxide synthase (NOS) pathway (N omega-nitro-L-arginine, 20 mg.kg-1.d-1 during 7 days) attenuated the systemic and coronary effects of bradykinin. HOE 140, a specific bradykinin B2 receptor antagonist, administered at a dose (30 micrograms/kg) sufficient to completely inhibit the systemic and coronary effects of exogenous bradykinin (1 microgram/kg, iv bolus), had no effect on baseline systemic and coronary hemodynamic parameters. HOE 140 had also no effect on the flow-dependent increase in large coronary artery diameter and on the relationship between flow debt and flow repayment volumes observed during myocardial reactive hyperemia. This lack of effect of HOE 140 persisted when experiments were repeated after NOS inhibition. We conclude that (a) exogenous bradykinin dilates large and small coronary arteries through a partially NO-mediated mechanism, and (b) endogenous bradykinin plays no role in the control of arterial pressure, heart rate, LV dP/dt max, basal and flow-stimulated coronary hemodynamics, both in control conditions and after subchronic inhibition of NOS in the conscious dog. |
| | |
Authors:
|
L Puybasset; J F Giudicelli; A Berdeaux |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Fundamental & clinical pharmacology Volume: 11 ISSN: 0767-3981 ISO Abbreviation: Fundam Clin Pharmacol Publication Date: 1997 |
Date Detail:
|
Created Date: 1997-09-24 Completed Date: 1997-09-24 Revised Date: 2005-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 8710411 Medline TA: Fundam Clin Pharmacol Country: FRANCE |
Other Details:
|
Languages: eng Pagination: 322-30 Citation Subset: IM |
Affiliation:
|
Département de Pharmacologie, Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acetylcholine
/
pharmacology Animals Blood Volume / drug effects Bradykinin / analogs & derivatives, pharmacology*, physiology* Coronary Circulation / drug effects*, physiology Dogs Heart Rate / drug effects Hyperemia / metabolism Nitric Oxide / metabolism Nitric Oxide Synthase / antagonists & inhibitors Nitroarginine / pharmacology Nitroglycerin / pharmacology Receptors, Bradykinin / antagonists & inhibitors Vasodilation / drug effects Vasodilator Agents / pharmacology* |
| Chemical | |
Reg. No./Substance:
|
0/Receptors, Bradykinin; 0/Vasodilator Agents; 10102-43-9/Nitric Oxide; 130308-48-4/icatibant; 2149-70-4/Nitroarginine; 51-84-3/Acetylcholine; 55-63-0/Nitroglycerin; 58-82-2/Bradykinin; EC 1.14.13.39/Nitric Oxide Synthase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The effects of ryanodine on calcium uptake by the sarcoplasmic reticulum of ischemic and reperfused ...
Next Document: Chronotropic and inotropic effects of terikalant on isolated, blood-perfused atrial and ventricular ...